Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Highly sensitive mapping of type II topoisomerase DNA cleavage sites with SHAN-seq

ABSTRACT: Highly sensitive mapping of type II topoisomerase DNA cleavage sites with SHAN-seq

PROVIDER: PRJNA1109861 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28984900_1.fastq.gz	Fastqsanger.gz
	SRR28984900_2.fastq.gz	Fastqsanger.gz
	SRR28984901_1.fastq.gz	Fastqsanger.gz
	SRR28984901_2.fastq.gz	Fastqsanger.gz
	SRR28984902_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 232

Similar Datasets

Highly sensitive mapping of type II topoisomerase DNA cleavage sites with SHAN-seq

Project description:Type II topoisomerases (topos) are a ubiquitous and essential class of enzymes that form transient enzyme-bound double-stranded breaks on DNA called cleavage complexes. The location and frequency of these cleavage complexes on DNA is important for cellular function, genomic stability, and a number of clinically important anticancer and antibacterial drugs, e.g., quinolones. We developed a simple high-accuracy end-sequencing (SHAN-seq) method to sensitively map type II topo cleavage complexes on DNA in vitro. Using SHAN-seq, we detected Escherichia coli gyrase and topoisomerase IV cleavage complexes at hundreds of sites on supercoiled pBR322 DNA, approximately one site every ten bp, with frequencies that varied by two-to-three orders of magnitude. These sites included previously identified sites and 20-50 fold more new sites. We show that the location and frequency of cleavage complexes at these sites are enzyme-specific and vary substantially in the presence of the quinolone, ciprofloxacin, but not with DNA supercoil chirality, i.e., negative vs. positive supercoiling. SHAN-seq’s exquisite sensitivity provides an unprecedented single-nucleotide resolution view of the distribution of gyrase and topoisomerase IV cleavage complexes on DNA. Moreover, the discovery that these enzymes can cleave DNA at orders of magnitude more sites than the relatively few previously known sites resolves the apparent paradox of how these enzymes resolve topological problems throughout the genome.

2024-08-06 | GSE267149 | GEO

Genome-wide maps of Topoisomerase IV binding and cleavage sites in E. coli

Project description:We report binding of Topoisomerase IV on the E. coli genome. We report the cleavage sites of Topoisomerase IV on the E. coli genome

2016-04-21 | GSE75641 | GEO

Genome-wide strand-specific mapping of cleavage sites induced by topoisomerase I in E. coli

Project description:Cleavage sites induced by the EcTopoI G116S M320V topoisomerase mutant were identified in E. coli genome with a single-nucleotide resolution using Topo-Seq.

2022-01-01 | GSE182473 | GEO

Megavirus shan

Project description:Megavirus shan Genome sequencing

| PRJNA281365 | ENA

CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq

Project description:CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq

| PRJNA313513 | ENA

Soil from Tian Shan

Project description:Soil from Tian Shan Metagenome

| PRJNA658179 | ENA

Transcription profiling of topoisomerase I inhibitor irinotecan (CPT-11) sensitive, resistant, and reverted human neuroblastomas

Project description:We have established a neuroblastoma model resistant in vivo to the topoisomerase I inhibitor irinotecan (CPT-11, Camptothecin-11, CAMPTOSAR®) in order to study resistance to these agents acquired in a therapeutic setting. Common mechanisms of resistance were not involved in this model and we thus explored the gene expression signature associated with resistance by comparing the transcriptomes of sensitive, resistant, and reverted tumours using high-throughput DNA microarrays.

2008-01-26 | E-TABM-211 | biostudies-arrayexpress

Topoisomerase 1 Regulates Gene Expression in Neurons through Cleavage Complex-Dependent and -Independent Mechanisms

Project description:Topoisomerase 1 (TOP1) inhibitors, including camptothecin and topotecan, covalently trap TOP1 on DNA, creating cleavage complexes (cc’s) that must be resolved before gene transcription and DNA replication can proceed. We previously found that topotecan reduces the expression of long (>100 kb) genes and unsilences the paternal allele of Ube3a in neurons. Here, we sought to evaluate overlap between TOP1cc-dependent and -independent gene regulation in neurons. To do this, we utilized Top1 conditional knockout mice, Top1 knockdown, the CRISPR-Cas9 system to delete Top1, TOP1 catalytic inhibitors that do not generate TOP1cc’s, and a TOP1 mutation (T718A) that stabilizes TOP1cc’s. We found that topotecan treatment significantly alters the expression of many more genes, including long neuronal genes, immediate early genes, and paternal Ube3a, when compared to Top1 deletion. Our data show that topotecan has a stronger effect on neuronal transcription than Top1 deletion, and identifies TOP1cc-dependent and -independent contributions to gene expression.

2016-05-27 | GSE79951 | GEO

Topoisomerase II inhibition involves characteristic chromosomal expression patterns: Doxorubicin study

Project description:A variety of important anticancer drugs kill cells by increasing cellular levels of topoisomerase II-DNA cleavage complex. The anthracycline anticancer drug doxorubicin forms a stable ternary complex with DNA and topoisomerase IIa, thereby inhibiting the normal function of the enzyme. In this study we found genes regulated by doxorubicin - induced and repressed - to be located much closer to each other than genes distributed randomly all over the genome (< 100 kbp). Keywords: Doxorubicin-treated human hepatocytes versus non-treated human hepatocytes

2008-10-01 | GSE11940 | GEO

Genome-wide strand-specific mapping of cleavage sites induced by topoisomerase I in E. coli

Project description:Genome-wide strand-specific mapping of cleavage sites induced by topoisomerase I in E. coli

| PRJNA756315 | ENA